Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 26, 2025 07:00 ET | Source: MoonLake Immunotherapeutics AG

MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic...